Treatment Experiences with CDK4&6 Inhibitors Among Women with Metastatic Breast Cancer: A Qualitative Study

Judith J Stephenson1 HealthCore, Inc., Wilmington, DE, USACorrespondence[email protected]

Jonathon Colby Gable2 Eli Lilly and Company, Indianapolis, IN, USA

Rebekah Zincavage1 HealthCore, Inc., Wilmington, DE, USA

Gregory L Price2 Eli Lilly and Company, Indianapolis, IN, USA

Collin Churchill2 Eli Lilly and Company, Indianapolis, IN, USA

Emily Zhu2 Eli Lilly and Company, Indianapolis, IN, USA

Keri Stenger2 Eli Lilly and Company, Indianapolis, IN, USA

Mukul Singhal1 HealthCore, Inc., Wilmington, DE, USA

Bal Nepal1 HealthCore, Inc., Wilmington, DE, USA

Michael Grabner1 HealthCore, Inc., Wilmington, DE, USA

Michael J Fisch3 AIM Specialty Health, Chicago, IL, USA

David Debono4 Anthem, Inc., Indianapolis, IN, USA

Amy R Geschwender5 SWOG Cancer Research Network, San Antonio, TX, USA

Gebra Cuyun Carter2 Eli Lilly and Company, Indianapolis, IN, USA

Your download is now in progress and you may close this window